3D Medicines Inc. Announces Early Completion of Phase III Clinical Trial Enrollment for Envafolimab in NSCLC
Key Points for Investors
- Early Completion of Enrollment: 3D Medicines Inc. (HKEX: 1244) has announced the early completion of patient enrollment for its Phase III clinical trial (Study No.: KN035-CN-017) of Envafolimab (KN035) for the neoadjuvant/adjuvant treatment of resectable non-small cell lung cancer (NSCLC).
- Collaboration: The trial is being co-developed with Alphamab Oncology (HKEX: 9966), underscoring strong partnerships in advancing innovative cancer therapies.
- Trial Details: The randomized, controlled, double-blind, multi-center trial is led by Professor Wang Changli of Tianjin Medical University Cancer Institute and Hospital and is being conducted at approximately 60 clinical research centers across China.
- Patient Enrollment: Target enrollment was approximately 390 patients with resectable Stage III NSCLC. The actual number of enrolled patients meets the protocol requirements and was completed ahead of schedule.
- Study Objectives: The primary endpoints include event-free survival (EFS), major pathological response (MPR) rate, and pathological complete response (pCR) rate, assessing the efficacy and safety of Envafolimab combined with platinum-containing doublet chemotherapy versus placebo plus the same chemotherapy.
Price-Sensitive and Shareholder-Relevant Information
- Accelerated Progress: Early completion of enrollment may signal strong investigator and patient interest, potentially expediting development timelines and regulatory submissions, which could be positively received by the market.
- Potential Milestone: If the Phase III trial results are positive, this could pave the way for new drug applications and commercial opportunities in the large NSCLC market, which is a significant value driver for shareholders.
- Regulatory and Data Risks: Management reminds investors that clinical trial outcomes are inherently uncertain, and subsequent processes—including statistical analysis, clinical report submission, and drug approval—may be affected by various risks and delays.
- Disclosure Commitment: The company has committed to providing timely updates on further developments as required by listing rules and relevant regulations.
Additional Details
- The trial is a multi-center effort, highlighting strong clinical collaboration across China.
- The advancement of this trial is a key development milestone for Envafolimab, which is being positioned as a potential new treatment option for patients with resectable Stage III NSCLC—a significant unmet medical need.
- Continued progress in this trial could impact future revenue streams and enhance the company’s competitive positioning in oncology.
- The announcement was made by Dr. Gong Zhaolong, Chairman of the Board, with the company’s board comprising both executive and independent directors.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Clinical trial outcomes are subject to significant risk and uncertainty. Investors should exercise caution and consider their own financial situation when making investment decisions.
